Melanoma in the brain: biology and therapeutic options

The development of brain metastases is a frequent occurrence in patients with disseminated melanoma and contributes to a disproportionate degree of morbidity and mortality. The prognosis is markedly reduced once a patient is diagnosed with central nervous system disease. Definitive therapeutic interventions with resection or stereotactic radiosurgery have improved outcomes and become standard approaches in the management of melanoma brain metastases. With the inclusion of whole-brain radiation in these interventions, there has been a reduction in local recurrences, but no improvement in the overall survival. Still, many patients are not candidates for surgery nor radiotherapy nor develop progressive central nervous system disease after definitive therapy. As new immune-based and targeted therapeutic agents are developed for the treatment of metastatic melanoma, understanding their activity in brain metastases is necessary for effective patient management. In this review, we discuss the biology of brain metastases in metastatic melanoma, current treatment approaches with surgery and radiotherapy, and future systemic therapeutic strategies.

[1]  D. Hoon,et al.  The metastatic microenvironment: Brain‐residing melanoma metastasis and dormant micrometastasis , 2012, International journal of cancer.

[2]  D. Rades,et al.  Dose‐escalation of whole‐brain radiotherapy for brain metastasis in patients with a favorable survival prognosis , 2012, Cancer.

[3]  J. Pichler,et al.  Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases , 2012, Acta Neuropathologica.

[4]  C. Tzen,et al.  Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma , 2011, Pigment cell & melanoma research.

[5]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[6]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[7]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[8]  R. Jain,et al.  The biology of brain metastases—translation to new therapies , 2011, Nature Reviews Clinical Oncology.

[9]  R. Dummer,et al.  An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Hodi,et al.  Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Ascierto,et al.  A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Tarek Mekhail,et al.  Adjuvant Whole-Brain Radiotherapy Versus Observation after Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study , 2011, Current oncology reports.

[13]  M. Mazumdar,et al.  Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post‐brain metastases survival , 2011, Cancer.

[14]  D. Schadendorf,et al.  Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma , 2011, Cancer.

[15]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  I. Fidler.  The role of the organ microenvironment in brain metastasis. , 2011, Seminars in cancer biology.

[17]  Dai Fukumura,et al.  Malignant cells facilitate lung metastasis by bringing their own soil , 2010, Proceedings of the National Academy of Sciences.

[18]  Y. Samuels,et al.  Analysis of the genome to personalize therapy for melanoma , 2010, Oncogene.

[19]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[20]  S. Rosenberg,et al.  Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy , 2010, Clinical Cancer Research.

[21]  M. Brown,et al.  Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. , 2010 .

[22]  Jeffrey W. Clark,et al.  Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. , 2010 .

[23]  D. Hoon,et al.  Chemokine-chemokine receptor axes in melanoma brain metastasis. , 2010, Immunology letters.

[24]  C. Garbe,et al.  Determinants of survival in patients with brain metastases from cutaneous melanoma , 2010, British Journal of Cancer.

[25]  C. Lebbé,et al.  Complete regression of a previously untreated melanoma brain metastasis with ipilimumab , 2010, Melanoma research.

[26]  Victor G Prieto,et al.  Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma , 2009, Clinical Cancer Research.

[27]  L. J. Eldik,et al.  Targeting protein kinases in central nervous system disorders , 2009, Nature Reviews Drug Discovery.

[28]  S. Powell,et al.  Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. , 2009, Anticancer research.

[29]  A. Sloan,et al.  Diagnosis and treatment of melanoma brain metastasis: a literature review. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[30]  P. Steeg,et al.  Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. , 2008, Cancer research.

[31]  M. Atkins,et al.  Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma , 2008, Cancer.

[32]  L. Carey,et al.  Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[33]  L. Bastholt,et al.  A phase II study of thalidomide in patients with brain metastases from malignant melanoma , 2008, Acta oncologica.

[34]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[35]  D. Schadendorf,et al.  B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis , 2007, PloS one.

[36]  J. Larkin,et al.  A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma , 2006, British Journal of Cancer.

[37]  K. Aldape,et al.  Activation of stat3 in human melanoma promotes brain metastasis. , 2006, Cancer research.

[38]  J. Menell,et al.  Temozolomide plus thalidomide in patients with brain metastases from melanoma , 2005, Cancer.

[39]  G H Barnett,et al.  Pathobiology of brain metastases , 2005, Journal of Clinical Pathology.

[40]  M. Gore,et al.  Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[42]  K. Shannon,et al.  Determinants of outcome in melanoma patients with cerebral metastases. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Rebecca Aucoin,et al.  Brain metastases in melanoma: roles of neurotrophins. , 2004, Neuro-oncology.

[44]  M. Weichenthal,et al.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Heerschap,et al.  Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. , 2003, Cancer research.

[46]  J. O'fallon,et al.  A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. , 2003, International journal of radiation oncology, biology, physics.

[47]  A. Hauschild,et al.  A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma , 2003, Melanoma research.

[48]  G. Barnett,et al.  Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma , 2002, Cancer.

[49]  J. Sosman,et al.  Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group , 2002, Journal of Cancer Research and Clinical Oncology.

[50]  P. Wesseling,et al.  Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. , 2002, Cancer research.

[51]  S. Steinberg,et al.  Safety and Efficacy of High-Dose Interleukin-2 Therapy in Patients With Brain Metastases , 2002, Journal of immunotherapy.

[52]  E. Messaris,et al.  Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? , 2000, Journal of neurosurgical sciences.

[53]  P. Levendag,et al.  Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. , 1999, International journal of radiation oncology, biology, physics.

[54]  W R Markesbery,et al.  Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. , 1998, JAMA.

[55]  H M Kooy,et al.  Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. , 1995, Journal of the National Cancer Institute.

[56]  L D Lunsford,et al.  A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. , 1994, International journal of radiation oncology, biology, physics.

[57]  Jochen Herms,et al.  Real-time imaging reveals the single steps of brain metastasis formation , 2010, Nature Medicine.

[58]  C. Balch,et al.  Cranial irradiation after surgical excision of brain metastases in melanoma patients , 2006, Annals of Surgical Oncology.

[59]  V. Budach,et al.  Temozolomide With or Without Radiotherapy in Melanoma With Unresectable Brain Metastases , 2005, Journal of Neuro-Oncology.

[60]  A. Friedman,et al.  Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. , 1998, Journal of neurosurgery.

[61]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.